中文摘要：

目的：探讨miR-192抑制物对于骨肉瘤细胞系SOSP_9607细胞增殖和凋亡的影响。方法：四甲基偶氮唑蓝（MTT）法测定细胞增殖抑制率，流式细胞仪测定细胞凋亡和周期。将SOSP-9607细胞分为对照组和实验组，对照组分为阴性对照和正常细胞对照组。实验组采用miR-192抑制物（hsa—miR-192 inhibitors）抑制SOSP_9607细胞内miR-192的活性。结果：与对照组相比，实验组显著抑制SOSP-9607细胞的增殖，有明显的剂量依赖性（P〈0．01）。随着浓度从50nmol／L逐渐增加至200nmol／L，抑制率逐渐增高（P〈0．01）。与对照组相比，实验组细胞周期G0/G1细胞比例显著增加，G2/M期细胞比例显著减少，S期细胞比例显著减少（P〈0．01）。实验组凋亡率（13．6±2．1）％与阴性对照组凋亡率（7．1±0．5）％相比明显增高（P〈0．01）。结论：miR-192抑制物通过抑制SOSP_9607细胞中miR-192的活性对SOSP细胞的增殖和凋亡发挥重要作用，可能成为骨肉瘤生物治疗的新靶点。

英文摘要：

Objective： To determine the effect of microRNA-192 inhibitors on the proliferation and apoptosis of human osteosarcoma cell line SOSP-9607. Methods： MTT assay was used to examine the inhibitory rate of the proliferation of SOSP-9607 cells by hsa-miR-192 inhibitors. Cultured SOSP-9607 cells were divided into two groups： the control group and the experiment group. The control group included two subgroups： the negative control subgroup and the normal control subgroup. In the experiment group, hsa-miR-192 inhibitors were used to inhibit the activity of miR-192. The experiment group included three subgroups with different doses. The apoptosis and the cell cycle were measured by flow cytometry. Cultured SOSP-9607 cells were also divided into two groups： the control group and the experiment group. Results： Hsa-miR-192 inhibitors inhibited SOSP-9607 cell proliferation in a dose-dependent manner （P〈0.01）, but no obvious effect was observed on cell proliferation in the control group （P〉0.05）. With the increase of concentration of inhibitors from 50 nmol/L to 200 nmol/L, the inhibitory rate was increased significantly （P〈0.01）. Hsa-miR-192 inhibitors increased the percentage of cells at G0/G1 phase and decreased the percentage of cells at G2/M phase and S .phase （P〈0.01）. The apoptosis ratio in the experiment group was 13.6%±2.1%, higher than that in the control group （7.1%±0.5%, P〈0.01）. Conclusion： The hsa-miR-192 inhibitors play an important role in the proliferation and apoptosis of SOSP-9607 cells through down-regulating miR-192, which may be a promising target for biotherapy of osteosarcoma.